Abbott Labs (ABT-N) Stock Predictions - Stockchase
WATCH LIST
111
Abbott Labs (ABT-N)

ON STOCKCHASE SINCE Jan 2001

biotechnology/pharmaceutical

Abbott Labs

ABT-N

62 watching          
Join the Discussion

Abbott Labs (ABT-N) SAVE Jan, 24, 2019, 4:33 am

69.91 1.58 (2.21%)

About Abbott Labs (ABT-N)

Abbott Laboratories is a multinational health care company with headquarters in Lake Bluff, Illinois. More at Wikipedia

What the experts are saying about ABT-N



  • All
  • Filtered
Signal Opinion Expert
BUY
Abbott Labs(ABT-N) 

January 23, 2019

Likes healthcare and ABT. It's moving higher. 1.8% dividend. Hold it. Fair valuation.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Likes healthcare and ABT. It's moving higher. 1.8% dividend. Hold it. Fair valuation.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Stan Wong

Director &, Private Wealth Manag...

Price Price
$69.920
Owned Owned
No

TOP PICK
Abbott Labs(ABT-N) 

January 10, 2019

They owned for a number of years. 35% of their business is in the US and 40% emerging markets. Well diversified. They have four divisions: nutritionals, established pharmaceuticals, generics and medical devices and diagnostics. She sees double digit growth in earnings. (Analysts’ price target is $78.57)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
They owned for a number of years. 35% of their business is in the US and 40% emerging markets. Well diversified. They have four divisions: nutritionals, established pharmaceuticals, generics and medical devices and diagnostics. She sees double digit growth in earnings. (Analysts’ price target is $78.57)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Christine Poole

CEO & Mana, GlobeInvest Capital ...

Price Price
$69.080
Owned Owned
Yes

BUY on WEAKNESS
Abbott Labs(ABT-N) 

August 23, 2018

Generally, don’t like to buy stocks when they hit all-time highs. He would wait for a better entry point. Great company. Not cheap but the multiple is not that extreme. (Analysts’ price target is $70.81)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Generally, don’t like to buy stocks when they hit all-time highs. He would wait for a better entry point. Great company. Not cheap but the multiple is not that extreme. (Analysts’ price target is $70.81)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Don Lato

President, Padlock Investment M...

Price Price
$65.830
Owned Owned
Yes

BUY
Abbott Labs(ABT-N) 

May 8, 2018

Their medical devices doing well as are their nutritional products given strong global demand; it's diversified and well-managed; pays over 2% dividend with growth. These are products we all need, and with an aging population, there will always be demand.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Their medical devices doing well as are their nutritional products given strong global demand; it's diversified and well-managed; pays over 2% dividend with growth. These are products we all need, and with an aging population, there will always be demand.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Christine Poole

CEO & Mana, GlobeInvest Capital ...

Price Price
$58.710
Owned Owned
Unknown

PAST TOP PICK
Abbott Labs(ABT-N) 

April 11, 2018

(A Top Pick May 17/17 Up 38%). He has been very happy with this.  It has devices, diagnostics and pharma.  The secular trends are positive with aging and obesity adding tailwinds.  Their June acquisition was very accretive. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick May 17/17 Up 38%). He has been very happy with this.  It has devices, diagnostics and pharma.  The secular trends are positive with aging and obesity adding tailwinds.  Their June acquisition was very accretive. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$58.450
Owned Owned
Yes

PAST TOP PICK
Abbott Labs(ABT-N) 

October 10, 2017

(A Top Pick May 17/17. Up 28%.) He likes that this isn’t a “one trick pony”. It has devices, diagnostics, nutrition, etc. A broad, diversified franchise, in a sector he approves of. Thinks it continues to make a lot of sense.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick May 17/17. Up 28%.) He likes that this isn’t a “one trick pony”. It has devices, diagnostics, nutrition, etc. A broad, diversified franchise, in a sector he approves of. Thinks it continues to make a lot of sense.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$55.400
Owned Owned
Yes

BUY on WEAKNESS
Abbott Labs(ABT-N) 

June 15, 2017

She continues to hold it and likes it.  They have done well this year so she would wait for a pull back to add to this position.  They are good at taking costs out.  They always increase their dividend and it should continue.  A good core holding.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

She continues to hold it and likes it.  They have done well this year so she would wait for a pull back to add to this position.  They are good at taking costs out.  They always increase their dividend and it should continue.  A good core holding.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Christine Poole

CEO & Mana, GlobeInvest Capital ...

Price Price
$48.120
Owned Owned
Yes

TOP PICK
Abbott Labs(ABT-N) 

May 17, 2017

Healthcare, as a sector, is neutral to tilting positively. Within that though, there are some industry groups that he likes, and some he doesn’t like. This one is in the subsector of medical devices, and is a great diversified player in that space. Their acquisition of St. Jude broadens their business and cardiovascular. Dividend yield of 2.4%. (Analysts’ price target is $48.)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Healthcare, as a sector, is neutral to tilting positively. Within that though, there are some industry groups that he likes, and some he doesn’t like. This one is in the subsector of medical devices, and is a great diversified player in that space. Their acquisition of St. Jude broadens their business and cardiovascular. Dividend yield of 2.4%. (Analysts’ price target is $48.)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$43.080
Owned Owned
Yes

COMMENT
Abbott Labs(ABT-N) 

May 10, 2017

Had owned this in the past. They made a number of acquisitions, so patience is required. Acquired St. Jude, which he had seen losing market share to Boston Scientific. One concern is that they bloated out their balance sheet for this acquisition. Trading at about 18X, so not terribly inexpensive. Also, there are still some balance sheet risk. If you are a long-term player, they have a proven ability to execute on their operations, and it will likely get re-rated.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Had owned this in the past. They made a number of acquisitions, so patience is required. Acquired St. Jude, which he had seen losing market share to Boston Scientific. One concern is that they bloated out their balance sheet for this acquisition. Trading at about 18X, so not terribly inexpensive. Also, there are still some balance sheet risk. If you are a long-term player, they have a proven ability to execute on their operations, and it will likely get re-rated.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$44.500
Owned Owned
No

BUY
Abbott Labs(ABT-N) 

March 21, 2017

This fits the profile of the type of company he would want to be adding to, on days like today. It is in the sector that is tremendously out of favour. The healthcare sector was the only sector that had a negative return last year. It has started to be a little more resilient this year, but relative to the history of healthcare, valuations are far more reasonable. He likes this because it has a history and a culture of growing the dividend. They have a wonderful brand name. 2.4% dividend yield.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

This fits the profile of the type of company he would want to be adding to, on days like today. It is in the sector that is tremendously out of favour. The healthcare sector was the only sector that had a negative return last year. It has started to be a little more resilient this year, but relative to the history of healthcare, valuations are far more reasonable. He likes this because it has a history and a culture of growing the dividend. They have a wonderful brand name. 2.4% dividend yield.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Dietze

Founder, P, Point View Wealth Ma...

Price Price
$44.800
Owned Owned
Unknown

COMMENT
Abbott Labs(ABT-N) 

February 22, 2017

This is sitting at around 17.5X forward earnings. The St. Jude acquisition was a big one for them. It expanded their balance sheet. They still have the Alere acquisition overhang. Have some things to chew through this year in order to get the multiple expansion up to something like 21X, where its direct competitors would trade at. If a longer-term holder, you do have some upside on this.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

This is sitting at around 17.5X forward earnings. The St. Jude acquisition was a big one for them. It expanded their balance sheet. They still have the Alere acquisition overhang. Have some things to chew through this year in order to get the multiple expansion up to something like 21X, where its direct competitors would trade at. If a longer-term holder, you do have some upside on this.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$45.010
Owned Owned
Unknown

WAIT
Abbott Labs(ABT-N) 

September 13, 2016

This does branded generics, nutritionals and medical devices. Their branded generics have good exposure to emerging markets, areas that need the drugs but don’t necessarily have the money to pay for the branded version. A well diversified company run by great management. They have announced 2 acquisitions. The overhang on the stock is that if they do both transactions, they may have to issue equity to fund some of that.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

This does branded generics, nutritionals and medical devices. Their branded generics have good exposure to emerging markets, areas that need the drugs but don’t necessarily have the money to pay for the branded version. A well diversified company run by great management. They have announced 2 acquisitions. The overhang on the stock is that if they do both transactions, they may have to issue equity to fund some of that.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Christine Poole

CEO & Mana, GlobeInvest Capital ...

Price Price
$40.640
Owned Owned
Yes

COMMENT
Abbott Labs(ABT-N) 

August 17, 2016

Healthcare is one of the sectors in the broad N.A. market that is heavily out of favour. This is in the healthcare and equipment space, and is not one of those business that is deeply, deeply undervalued right now. It is in the process of trying to do a merger, and he is very reticent about recommending a stock that is in the process of having a merger in the US. He would much prefer an Allergan (AGN-N) where there is no potential deal risk at all. Abbott Labs is trading at 20X this year’s earnings, and Allergan is trading at about 18X, and is a much bigger growth story. Dividend yield of 2.33%. (See Top Picks.)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Healthcare is one of the sectors in the broad N.A. market that is heavily out of favour. This is in the healthcare and equipment space, and is not one of those business that is deeply, deeply undervalued right now. It is in the process of trying to do a merger, and he is very reticent about recommending a stock that is in the process of having a merger in the US. He would much prefer an Allergan (AGN-N) where there is no potential deal risk at all. Abbott Labs is trading at 20X this year’s earnings, and Allergan is trading at about 18X, and is a much bigger growth story. Dividend yield of 2.33%. (See Top Picks.)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Bruce Tatters

Founding P, Triumph Asset Manage...

Price Price
$44.680
Owned Owned
Unknown

DON'T BUY
Abbott Labs(ABT-N) 

July 28, 2016

Significant emerging markets exposure.  He sees better risk reward in other parts of the healthcare market.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Significant emerging markets exposure.  He sees better risk reward in other parts of the healthcare market.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Andy Nasr

VP & Inves, Sentry Investments...

Price Price
$44.450
Owned Owned
No

COMMENT
Abbott Labs(ABT-N) 

June 22, 2016

Has 4 businesses, an established pharma, labs division, diagnostic division and a medical device division. Has owned this for some time. Recently made a couple of acquisitions, so the valuation hasn’t kept up with its peers. Part of the reason is because of hair on some of the acquisitions. They are looking to acquire another company for about $5 billion + $3 billion in debt, which would be complementary to their monitoring devices. Their larger acquisition is St. Jude Medical, highly complementary and a leader in cardiac rhythmic management. Paid $25 billion with about $5 billion debt. This is going to be cash and stock. A situation where patience is required. You have 6 months of a bit of noise around the acquisitions, and after that they will be integrated and begin their growth. He is writing options on this.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Has 4 businesses, an established pharma, labs division, diagnostic division and a medical device division. Has owned this for some time. Recently made a couple of acquisitions, so the valuation hasn’t kept up with its peers. Part of the reason is because of hair on some of the acquisitions. They are looking to acquire another company for about $5 billion + $3 billion in debt, which would be complementary to their monitoring devices. Their larger acquisition is St. Jude Medical, highly complementary and a leader in cardiac rhythmic management. Paid $25 billion with about $5 billion debt. This is going to be cash and stock. A situation where patience is required. You have 6 months of a bit of noise around the acquisitions, and after that they will be integrated and begin their growth. He is writing options on this.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$38.740
Owned Owned
Yes

Showing 1 to 15 of 111 entries
Successfully Saved Company
Successfully Saved Company